Compare DexCom, Inc. (DXCM) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

The iShares Broad USD Investment Grade Corporate Bond ETF (USIG) trades at $50.73, showing modest daily gains. Technical indicators signal a bearish trend with moving averages and key momentum readings in sell territory. The ETF maintains regular dividend distributions, with recent payments of $0.20-$0.21 per share. Short interest surged 63.4% in April 2026, indicating growing bearish sentiment among some investors.

As a fixed-income ETF tracking investment-grade corporate bonds, USIG offers exposure to credit markets rather than equity fundamentals. The outlook depends on interest rate movements and credit spread dynamics. Key risks include rising rates compressing bond prices and deteriorating corporate credit quality. The substantial short interest increase suggests institutional skepticism about near-term performance.